210344-97-1
210344-97-1 結(jié)構(gòu)式
基本信息
化合物Z-YVAD-FMK
L-Alaninamide, N-[(phenylmethoxy)carbonyl]-L-tyrosyl-L-valyl-N-[(1S)-3-fluoro-1-(2-methoxy-2-oxoethyl)-2-oxopropyl]- (9CI)
物理化學(xué)性質(zhì)
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2024/11/08 | S8507 | MVPQJUFFTWWKBT-LBDWYMBGSA-N Z-YVAD-FMK | 210344-97-1 | 5mg | 4370元 |
| 2024/11/08 | S8507 | Z-YVAD-FMK | 210344-97-1 | 10mM (1mL in DMSO) | 5135.13元 |
| 2024/11/08 | S8507 | Z-YVAD-FMK | 210344-97-1 | 25mg | 13423.9元 |
常見問題列表
| Target | Value |
|
caspase-1
() |
Z-YVAD-FMK (100 μM; 24 hours) significantly downregulated the growth inhibition induced by butyrate in Caco-2 cells. Z-YVAD-FMK (20 μM; pre 1 hour; 24 hours) attenuates the apoptotic induction of III-10 on both HepG2 and BEL-7402 cells, the apoptotic rate of -10 on HepG2 cells is reduced by Z-VAD-FMK from 19.88% to 8.34%, while that on BEL-7402 cells is reduced from 17.56% to 11.98%. Z-YVAD-FMK (1-10 μM; 24 hours) shows inhibitory effect in various cells against TNFr- or anti-CD95-induced cell death, exhibits IC 50 values of 0.0015 μM (Murine hepatocytes), 0.027 μM (Murine hepatocytes), 4.8 μM (HepG2), 5.8 μM (HepG2), 1.6 μM (Hela) and 1.1 μM (Jurkat), respectively.
Cell Viability Assay
| Cell Line: | Caco-2 cells |
| Concentration: | 0-100 μM |
| Incubation Time: | 24 hours |
| Result: | Inhibited Caco-2 cells growth. |
Apoptosis Analysis
| Cell Line: | BEL-7402 and HepG2 cells |
| Concentration: | 20 μM |
| Incubation Time: | Pre 1 hour; 24 hours |
| Result: | Induced a caspase-dependent apoptosis in cells. |
Z-VAD-FMK (intraperitoneal?injection; 10mg/kg; pre- 30 minutes) significantly delayed preterm delivery at 18 hours, but after 36 hours treatment, non different exists between Z-VAD-FMK-pretreated and control groups.
| Animal Model: | Day 14.5 pregnant CD1 mice |
| Dosage: | 10?mg/kg |
| Administration: | Intraperitoneal?injection; 10mg/kg; pre-30 minutes |
| Result: | Prevented HK-GBS-induced preterm delivery. |